X
Astellas maintains lead over Daiichi Sankyo with CHMP okay for Xospata
https://pharmaphorum.com/news/astellas-maintains-lead-over-daiichi-sankyo-with-aml-drug-xospata/
acute myeloid leukaemia
Pfizer will have to cut price of AML drug Mylotarg after NICE ruling
NICE blocks access to 65% of patients on cost grounds
FDA reapproves Pfizer’s Mylotarg leukaemia drug
FDA gives green light after 7-year absence
The curious case of Mylotarg: Pfizer’s leukaemia drug set to return
Mylotarg backed by advisers after withdrawal in 2010.
Seattle Genetics leukaemia trial on hold after 4 deaths
FDA concerned over potential liver toxicity.